Whether a drug proven to be effective in human RAFLS model can be directly taken to clinical trials?
you have two questions. Q1/ Why are RASLF used in anti-arthritic preclinical studies? Well, they provide a good model for synovial hyperplasia ( a hallmarlk of arthritis), in that we can directly monitor the effect of potential antiarthritc drugs against excessively growing fibroblasts that are taken directly for arthritic patients. Condrocytes (erosin of in arthritis another hallmark) can be tricky to culture. Many other cell types should also be studied (macrophages, osteoblasts/clasts) prior to any further in vitro claims of efficacy in arthritis. These will provide evidence of efficacy prior to moving the study to a higher organism with joints that can develop, and be treated for, arthritis (i.e. collagen or antigen-induced arthritis in rats or mice)
Q2/Whether s a drug can go directly for RASLF to clinical trial? in a word; No. You must always have evidence in a preclinical setting of efficacy and safety in a laboratory species with the arthritic disease AND in a normal healthy (phase 1-like preclinical) animal; such as rats, mice rabbits and even dogs. All global drug authorities (like FDA and EuMA) will demand enough preclinical evidence in a lab species, NOT just cells, prior to moving to hum an trials.
Hypothetical question to you; would you take a drug for your arthritis that has only ever been given to cells, shown non cytotoxic (therefore 'safe') and effective at, say, reducing fibroblast proliferation, and expect it to work for your condition??
I hope this helps! good luck
- Badges
- Science topic
- Similar topics
- Mathematical Sciences
- Statistics
- Statistical Software
- SPSS